C. difficile causes ten-fold more infections and excess healthcare costs than all other CDC Urgent Threat Pathogens combined. LPOXY’s upcoming STOP-Cdiff clinical trial will evaluate SIDIPREV™ in hospitalized elderly adults receiving broad-spectrum antibiotics, the highest-risk group for C. difficile infection. 

A non-antibiotic approach, which means no tug-of-war with resistance and none of the stewardship headaches that bog down traditional drug rollouts. Article on LinkedIn by Jesse Landry

Proceeds will fund the SIDIPREV™ Trial On Prevention of C.difficile Infections, positioned to become the first prevention against C.difficile, a deadly infection that claims 80 U.S. lives daily and lacks any approved preventive therapy.

Select assets have been acquired from Xeno Biosciences by LPOXY. These include data generated in Xeno’s Phase I and Ib clinical trials, which validates the safety of the Active Pharmaceutical Ingredient shared by Xeno’s and LPOXY’s drug products.

Larry Sutton, MD, PhD, CEO, will present at Biotech Showcase an overview of LPOXY’s mission to address the urgent need for innovative non-antibiotic solutions to prevent C. difficile infections, a significant and growing healthcare challenge.

January 13-16. BIO Partnering @ JPM Week is an invaluable opportunity for us to connect with investors and strategic partners who share our commitment to addressing the global healthcare burden posed by bacterial infections.